IMRX (STOCKS)
Immuneering Corporation Class A Common Stock
$4.170000
-0.020000 (-0.48%)
Prev close: $4.190000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Benjamin J. Zeskind
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $270.76M
- Employees
- 54
- P/E (TTM)
- -3.59
- P/B (TTM)
- 1.31
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.21 | $-0.26 | +0.0470 | +18.29% |
|
Dec 2025 (Q4)
|
$-0.18 | $-0.32 | +0.1396 | +43.68% |
|
Sep 2025 (Q3)
|
$-0.38 | $-0.40 | +0.0198 | +4.95% |
|
Jun 2025 (Q2)
|
$-0.40 | $-0.42 | +0.0233 | +5.50% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $59.23M |
| Research and Development | $41.22M |
| Other Operating Expenses | $18.00M |
| Operating Income/Loss | -$59.23M |
| Income/Loss From Continuing Operations After Tax | -$54.44M |
| Income/Loss From Continuing Operations Before Tax | -$54.44M |
| Net Income/Loss | -$54.44M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$54.44M |
| Net Income/Loss Available To Common Stockholders, Basic | -$54.44M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.06 |
| Diluted Earnings Per Share | -$1.06 |
| Basic Average Shares | 73,140,987 |
| Diluted Average Shares | 73,140,987 |
| Assets | $214.81M |
| Current Assets | $161.41M |
| Noncurrent Assets | $53.40M |
| Fixed Assets | $937.01K |
| Other Non-current Assets | $52.46M |
| Liabilities | $8.29M |
| Current Liabilities | $4.97M |
| Accounts Payable | $1.45M |
| Other Current Liabilities | $3.52M |
| Noncurrent Liabilities | $3.32M |
| Equity | $206.52M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $206.52M |
| Liabilities And Equity | $214.81M |
| Net Cash Flow From Operating Activities | -$49.70M |
| Net Cash Flow From Operating Activities, Continuing | -$49.70M |
| Net Cash Flow From Investing Activities | -$151.80M |
| Net Cash Flow From Investing Activities, Continuing | -$151.80M |
| Net Cash Flow From Financing Activities | $212.95M |
| Net Cash Flow From Financing Activities, Continuing | $212.95M |
| Net Cash Flow | $11.46M |
| Net Cash Flow, Continuing | $11.46M |
| Comprehensive Income/Loss | -$54.68M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$54.68M |
| Other Comprehensive Income/Loss | -$40.25M |